 |
|
|
| |
Safety and Pharmacokinetics of BJT-628, an Orally Available Liver-Targeted HBV Transcript Inhibitor for the Treatment of Chronic Hepatitis B in Healthy Volunteers
|
| |
| |
AASLD 2025 Nov 7-11 Wash DC
Edward Gane1, Christian Schwabe2, Jeff Zablocki4, Nancy Shulman4, Raj Bhardwaj3, Joelle Batonga3, Hassan Javanbakht4, Susanna K Tan
1 University of Auckland, Auckland, New Zealand, 2 New Zealand Clinical Research, Auckland, New Zealand, 3 Certara, Inc., New Jersey, USA, 4Bluejay Therapeutics, Redwood City, CA, USA
|
| |
|
|
|
|
|
